Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized 4.2% sodium bicarbonate in ventilated COVID-19 pneumonia (Phase 2)
2021-001665-20Phase 2Active
- Sponsor
- Semmelweis University
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus pneumonia and coronavirus disease 2019 (COVID-19) comparing Nebulized 4.2% sodium bicarbonate with Control (standard of care nebulization) (2 arms). Primary endpoint: Change in PaO2/FiO2 (Horowitz index). Started Mar 2021; status: active.
02
Drugs
sodium bicarbonate
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-001665-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001665-20.